What is the ticker symbol for Stoke Therapeutics?

Stoke Therapeutics trades under the ticker STOK on NASDAQ.

What sector does Stoke Therapeutics operate in?

Stoke Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze STOK in a portfolio?

PortView shows STOK's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Stoke Therapeutics (STOK) Stock Analysis

NASDAQHealthcareBiotechnology

$26.17+0.14%

1-year price historyRange $22.37 – $38.35

52-week range$26.17

$20.32$40.22

Track STOK in your portfolio for free · Portfolio tracker

What Stoke Therapeutics does

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.

Key metrics

Market cap

$1.69B

P/E (TTM)

-7.83

EPS (TTM)

$-3.34

Beta

1.26

Dividend yield

0.00%

Revenue / share

$0.42

50-day avg

$27.78

200-day avg

$30.98

52-week high

$40.22

52-week low

$20.32

CEO

Ian F. Smith

ETFs linked to STOK

Broad-market and Healthcare sector ETFs an investor holding Stoke Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how STOK fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze STOK in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Stoke Therapeutics?: Stoke Therapeutics trades under the ticker STOK on NASDAQ.
Which exchange is STOK listed on?: STOK is listed on NASDAQ.
What sector does Stoke Therapeutics operate in?: Stoke Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze STOK in a portfolio?: PortView shows STOK's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.